KDventures (KDEV BTA B) Stock Overview

A venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. More details

KDEV BTA B fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings have declined by 20.4% per year over past 5 years

Makes less than USD$1m in revenue (SEK2M)

Shares are highly illiquid

+ 1 more risk

KDEV BTA B Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

1.3k

US$21.53

71.8% undervalued

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

KDventures AB Competitors

Price History & Performance

Summary of share price highs, lows and changes for KDventures
Historical stock prices
Current Share Price	SEK 0.28
52 Week High	SEK 0.30
52 Week Low	SEK 0.24
Beta	0.39
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	3.52%

Recent updates

Shareholder Returns

	KDEV BTA B	SE Pharmaceuticals	SE Market
7D	12.0%	-18.6%	0.08%
1Y	n/a	-21.1%	2.6%

Return vs Industry: Insufficient data to determine how KDEV BTA B performed against the Swedish Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how KDEV BTA B performed against the Swedish Market.

Price Volatility

Is KDEV BTA B's price volatile compared to industry and market?
KDEV BTA B volatility
KDEV BTA B Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in SE Market	11.8%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: KDEV BTA B's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: Insufficient data to determine KDEV BTA B's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2003	8	Viktor Drvota	www.karolinskadevelopment.com

KDventures AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark.

KDventures AB Fundamentals Summary

How do KDventures's earnings and revenue compare to its market cap?
KDEV BTA B fundamental statistics
Market cap	SEK 192.28m
Earnings (TTM)	-SEK 135.74m
Revenue (TTM)	SEK 1.74m

106.1x

P/S Ratio

-1.4x

P/E Ratio

Is KDEV BTA B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KDEV BTA B income statement (TTM)
Revenue	SEK 1.74m
Cost of Revenue	SEK 0
Gross Profit	SEK 1.74m
Other Expenses	SEK 137.48m
Earnings	-SEK 135.74m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Feb 13, 2026

Earnings per share (EPS)	-0.21
Gross Margin	100.00%
Net Profit Margin	-7,810.36%
Debt/Equity Ratio	0%

How did KDEV BTA B perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/02/12 19:46
End of Day Share Price	2026/02/12 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

KDventures AB is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Johan Löchen	ABG Sundal Collier Sponsored
Espen Jørgensen	DNB Carnegie
Klas Palin	DNB Carnegie Commissioned Research

KDventures ABOM:KDEV BTA B Stock Report